Chronic pancreatitis- Pipeline Insight, 2025
Description
DelveInsight’s, “Chronic pancreatitis- Pipeline Insight, 2025” report provides comprehensive insights about 5+companies and 5+pipeline drugs in Chronic pancreatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Chronic pancreatitis: Overview
Chronic pancreatitis is a condition where the pancreas (a small organ located behind the stomach and below the ribcage) becomes permanently damaged from inflammation. It is a progressive inflammatory disorder that leads to irreversible destruction of exocrine and endocrine pancreatic parenchyma caused by atrophy and/or replacement with fibrotic tissue. Since the main function of the pancreas is to produce digestive enzymes and hormones, such as insulin, that regulate blood sugar levels, and therefore, damage to the pancreas can cause problems with digestion, absorption of nutrients, and production of insulin. As a result, people with chronic pancreatitis can lose weight, experience diarrhea, become malnourished with vitamin deficiencies and can develop diabetes. The main symptom can include abdominal pain and Pancreatic insufficiency. The symptoms can take several years to occur and most cases of chronic pancreatitis are caused by long-standing over use of alcohol. Less common causes of chronic pancreatitis include genetic disorders, such as cystic fibrosis, hereditary pancreatitis, or autoimmune pancreatitis. Rarely, an attack of severe acute pancreatitis causes permanent scarring (fibrosis) of the pancreas that leads to chronic pancreatitis. In some people, chronic pancreatitis develops when the pancreatic duct is blocked (obstructed) by stones or a tumor. The clinical presentation of the patients with chronic pancreatitis, most commonly present with the recurrent episodes of acute pancreatitis. This will often progress to chronic abdominal pain that is characteristically located in the epigastrium and radiates to the back. There is no single test that can be used to diagnose chronic pancreatitis and it is generally made based on a patient's history, clinical presentation, and imaging findings. Diagnosing chronic pancreatitis in its early stages is often difficult. Many pancreatic cells can be damaged before abnormalities show up on tests, X-rays or scans. The diagnostic tests use for the diagnosis include blood tests which will look for high levels of two pancreatic enzymes, amylase and lipase. Apart from this, imaging techniques such as CT scan, ultrasound, and magnetic resonance cholangiopancreatography can also be use in the diagnosis process.
The goals of all treatment modalities include improving the pain, quality of life, and decreased morbidity and mortality from endocrine and exocrine pancreatic dysfunction. Treatment of chronic pancreatitis can be medical, endoscopic, or surgical.
Report Highlights
This segment of the Chronic pancreatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic pancreatitis: Emerging Drugs
Further product details are provided in the report……..
Chronic pancreatitis: Therapeutic Assessment
This segment of the report provides insights about the different Chronic pancreatitis drugs segregated based on following parameters that define the scope of the report, such as:
Phases
DelveInsight’s report covers around 5+products under different phases of clinical development like
Chronic pancreatitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Chronic pancreatitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic pancreatitis drugs.
Chronic pancreatitis: Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Chronic pancreatitis: Overview
Chronic pancreatitis is a condition where the pancreas (a small organ located behind the stomach and below the ribcage) becomes permanently damaged from inflammation. It is a progressive inflammatory disorder that leads to irreversible destruction of exocrine and endocrine pancreatic parenchyma caused by atrophy and/or replacement with fibrotic tissue. Since the main function of the pancreas is to produce digestive enzymes and hormones, such as insulin, that regulate blood sugar levels, and therefore, damage to the pancreas can cause problems with digestion, absorption of nutrients, and production of insulin. As a result, people with chronic pancreatitis can lose weight, experience diarrhea, become malnourished with vitamin deficiencies and can develop diabetes. The main symptom can include abdominal pain and Pancreatic insufficiency. The symptoms can take several years to occur and most cases of chronic pancreatitis are caused by long-standing over use of alcohol. Less common causes of chronic pancreatitis include genetic disorders, such as cystic fibrosis, hereditary pancreatitis, or autoimmune pancreatitis. Rarely, an attack of severe acute pancreatitis causes permanent scarring (fibrosis) of the pancreas that leads to chronic pancreatitis. In some people, chronic pancreatitis develops when the pancreatic duct is blocked (obstructed) by stones or a tumor. The clinical presentation of the patients with chronic pancreatitis, most commonly present with the recurrent episodes of acute pancreatitis. This will often progress to chronic abdominal pain that is characteristically located in the epigastrium and radiates to the back. There is no single test that can be used to diagnose chronic pancreatitis and it is generally made based on a patient's history, clinical presentation, and imaging findings. Diagnosing chronic pancreatitis in its early stages is often difficult. Many pancreatic cells can be damaged before abnormalities show up on tests, X-rays or scans. The diagnostic tests use for the diagnosis include blood tests which will look for high levels of two pancreatic enzymes, amylase and lipase. Apart from this, imaging techniques such as CT scan, ultrasound, and magnetic resonance cholangiopancreatography can also be use in the diagnosis process.
The goals of all treatment modalities include improving the pain, quality of life, and decreased morbidity and mortality from endocrine and exocrine pancreatic dysfunction. Treatment of chronic pancreatitis can be medical, endoscopic, or surgical.
- Medical: For milder types of pain, medications such as acetaminophen (Tylenol) or ibuprofen (Advil, Motrin and others) are use and many people need narcotic medications to control the pain.
- Endoscopy: Endoscopy can be used to treat symptomatic strictures, stones, and pseudocysts. Endoscopic drainage of pseudocysts has a similar rate of pain relief as surgery, with equivalent or lower mortality.
- Surgery: surgical treatment may be an option if the pancreatic ducts are dilated or if there is an inflammatory mass in one region of the pancreas. There are different techniques that remove different amounts of the pancreas. The one chosen depends on the severity of the patient’s condition.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Chronic pancreatitis R&D. The therapies under development are focused on novel approaches to treat/improve Chronic pancreatitis.
This segment of the Chronic pancreatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic pancreatitis: Emerging Drugs
- FW-EPI (adrulipase): First Wave BioPharma, Inc.
- CM4620: calcimedica
Further product details are provided in the report……..
Chronic pancreatitis: Therapeutic Assessment
This segment of the report provides insights about the different Chronic pancreatitis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Chronic pancreatitis
Phases
DelveInsight’s report covers around 5+products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Chronic pancreatitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Chronic pancreatitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic pancreatitis drugs.
Chronic pancreatitis: Report Insights
- Chronic pancreatitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chronic pancreatitis drugs?
- How many Chronic pancreatitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic pancreatitis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic pancreatitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chronic pancreatitis and their status?
- What are the key designations that have been granted to the emerging drugs?
- First Wave BioPharma, Inc.
- calcimedica
- Theraly Fibrosis
- FW-EPI (adrulipase)
- CM4620
- TLY012
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Chronic pancreatitis: Overview
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Chronic pancreatitis– DelveInsight’s Analytical Perspective
- Mid Stage Products (Phase II)
- Comparative Analysis
- FW-EPI (adrulipase): First Wave BioPharma, Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- TLY012: Theraly Fibrosis
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- CM4620: calcimedica
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Chronic pancreatitis Key Companies
- Chronic pancreatitis Key Products
- Chronic pancreatitis- Unmet Needs
- Chronic pancreatitis- Market Drivers and Barriers
- Chronic pancreatitis- Future Perspectives and Conclusion
- Chronic pancreatitis Analyst Views
- Chronic pancreatitis Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
